Novel Treatment Combinations in Development for AML: The Role of Hypomethylating Agents

Novel Treatment Combinations in Development for AML: The Role of Hypomethylating Agents

CME, CPE
Ehab Atallah, MD
Release Date: October 30, 2017

Expiration Date: October 30, 2018

There is a significant unmet need in existing treatment paradigms for patients with acute myeloid leukemia (AML) due to poor survival and intolerability to cytotoxic chemotherapy, especially for a generally older patient population. Hypomethylating agents (HMAs) have demonstrated a benefit in patients with AML, especially those who require less aggressive therapy, but there is a need for improved efficacy and survival outcomes. In this activity, participants will learn about HMAs in existing treatment paradigms, as well as the investigational landscape of novel therapies in combination with HMAs, and their potential impact on treatment outcomes for patients with AML.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.

Begin

EHA 2017 Congress Highlights in Acute Myeloid Leukemia

EHA 2017 Congress Highlights in Acute Myeloid Leukemia

CME, CPE, CNE
Ehab Atallah, MD; Jorge E. Cortes, MD; Naval Daver, MD; Keith W. Pratz, MD; Eytan M. Stein, MD; Richard M. Stone, MD
Release Date: July 21, 2017

Expiration Date: July 21, 2018

In this activity, participants will learn about key highlights of the latest and most impactful data in acute myeloid leukemia (AML), presented at the 2017 European Hematology Association (EHA) 22nd Congress.

Chapter 1: Combination Therapy with Novel Agents and Chemotherapy Improves Survival in Diverse Subsets of AML Patients

Chapter 2: Safety and Efficacy of Enasidenib in Patients with Mutant-IDH2 Relapsed AML

Chapter 3: Improving Efficacy of Mutation-specific Therapeutic Options in AML: Emerging Data and Novel Agents

Chapter 4: Improved Efficacy, Safety with CPX-351 in Older Adults with Newly Diagnosed Therapy Related AML

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.

Begin

Tailoring Therapy to Older Patients with Acute Myeloid Leukemia

Tailoring Therapy to Older Patients with Acute Myeloid Leukemia

CME, CPE
Aziz Nazha, MD
Release Date: September 14, 2017

Expiration Date: September 14, 2018

Acute myeloid leukemia (AML) is generally a hematologic malignancy of older adults, with approximately 60% of newly diagnosed AML patients being 60 or older. Older patients pose unique therapeutic challenges that have been largely unmet to date. This activity will review and discuss decision-making strategies outlining when and how to treat this patient population in your practice. In addition, Dr. Nazha will provide an overview of the current treatment paradigms available, as well as agents currently approved or under investigation which may have a potential role in the outcome of the older patient with AML.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.

Begin

Breaking New Ground in AML: Practical Applications of Emerging Treatment Options

Breaking New Ground in AML: Practical Applications of Emerging Treatment Options

CME, CPE, CNE
Guillermo Garcia-Manero, MD; Jeffrey E. Lancet, MD; Elli Papaemmanuil, PhD; Richard Stone, MD
Release Date: July 21, 2017

Expiration Date: July 21, 2018

This activity has been developed from a live symposium held in conjunction with a clinical oncology meeting held in June 2017, focusing on the newest advancements in acute myeloid leukemia (AML). Drawing upon both clinical trial data and analysis of case vignettes, a distinguished faculty panel discusses not only new and emerging strategies in the diagnosis, prognosis, and treatment of AML, but also how these critical new advances will change practice in the near future.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Astellas, Celgene Corporation, Helsinn, Incyte Corporation, and Jazz Pharmaceuticals.

Begin

Back to Basics in the Diagnosis and Prognosis of Acute Myeloid Leukemia

Back to Basics in the Diagnosis and Prognosis of Acute Myeloid Leukemia

CME, CPE
Keith W. Pratz, MD
Release Date: May 31, 2017

Expiration Date: May 31, 2018

The diagnosis and prognosis of acute myeloid leukemia (AML) is challenging due to complexities regarding disease biology, classification, and molecular markers. In May 2016, the World Health Organization (WHO) revised their classification of myeloid neoplasms and acute leukemia. Updates to practice guidelines and publication of data regarding investigational diagnostic and prognostic strategies are also changing how patients with suspected AML are diagnosed and assessed. In this activity, participants will learn the basics of diagnosing and prognosticating patients with AML using the recently revised clinical criteria, and will gain greater insight into today’s real-world issues associated with diagnosis, as well as diagnostic criteria and prognostic factors under investigation.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Helsinn, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.

Begin

Exploring Epigenetics in AML Oncogenesis

Exploring Epigenetics in AML Oncogenesis

CME, CPE
Farhad Ravandi, MD
Release Date: June 23, 2017

Expiration Date: June 23, 2018

In acute myeloid leukemia (AML), several epigenetic pathways have been implicated in disease pathogenesis, including DNA methylation, histone acetylation, and histone methylation. Ongoing research is focusing on these epigenetic pathways for the development of novel agents and regimens across the disease lifecycle. Join Dr. Ravandi as he describes the molecular and cellular processes that are driving oncogenesis in AML, how the mechanisms of action of several new and emerging agents in AML target specific genetic mutations, and the critical implications for clinical practice.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Helsinn, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.

Begin

Emerging Agents Impacting Future Treatment Strategies in AML

Emerging Agents Impacting Future Treatment Strategies in AML

CME, CPE
Pinkal Desai, MD, MPH
Release Date: May 31, 2017

Expiration Date: May 31, 2018

The treatment landscape for acute myeloid leukemia (AML) is rapidly evolving due to a multitude of investigational therapies across various patient populations. Recently, there have been a number of agents designated as breakthrough therapy by the Food and Drug Administration (FDA), including venetoclax, CPX-351, midostaurin and pracinostat, in combination with azacitidine. In addition, there are a number of novel agents in late-stage clinical development, reinforcing the potential availability of new treatment options in the near future. In this activity, Dr. Desai will discuss novel therapies being studied in clinical trials for different patient populations, as well as the future direction of treatment strategies in AML.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Helsinn, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.

Begin